ArticleExploratory research in clinical and social pharmacy2026
Development of a novel adherence scale for antidepressants in pregnancy: Results from a cross-sectional study.
Article in Exploratory research in clinical and social pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Adherence to antidepressant pharmacotherapy is essential for optimal treatment. Its assessment during pregnancy is challenging, as existing self-report scales are not tailored to pregnancy. Aim: This study aimed to develop a self-report scale to assess antidepressant adherence in pregnancy and evaluate its psychometric properties. Methods: This cross-sectional study used an anonymous online questionnaire administered in Norway between February and March 2022. Participants were pregnant or up-to-12-month postpartum individuals who had used antidepressants during pregnancy. Results: Ninety participants who used antidepressants during pregnancy completed the MAMP-AD scale. The final 15-item MAMP-AD scale had a score range of 0 to 48, with higher scores indicating higher adherence. EFA identified three distinct factors: 1) Minimizing exposure, 2) Barriers to antidepressant use, and 3) Benefits of antidepressant use. These explained 81.7% of the total variance in the MAMP-AD scale. The scale showed acceptable reliability (Cronbach's α = 0.80). Higher MAMP-AD scores were negatively associated with depression severity, supporting construct validity. Conclusion: The MAMP-AD is a newly developed, self-report scale for measuring antidepressant adherence in pregnancy, showing preliminary evidence of acceptable reliability and validity. Further research is needed to confirm the scale's psychometric properties and clinical utility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.